Mazdutide
Clinical data | |
---|---|
Other names | IBI362; LY3305677 |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
UNII | |
Chemical and physical data | |
Formula | C207H317N45O65 |
Molar mass | 4476.063 g·mol−1 |
3D model (JSmol) | |
| |
|
Mazdutide (also known as IBI362 or LY3305677) is a dual agonist of the GLP-1 receptor and glucagon receptor. It is an analog of oxyntomodulin (OXM).[1][2][3] The drug is developed by Eli Lilly and is currently in a Phase II study.[4]
References
[edit]- ^ Jiang, Hongwei; Pang, Shuguang; Zhang, Yawei; Yu, Ting; Liu, Meng; Deng, Huan; Li, Li; Feng, Liqi; Song, Baili; Han-Zhang, Han; Ma, Qingyang; Qian, Lei; Yang, Wenying (24 June 2022). "A phase 1b randomised controlled trial of a glucagon-like peptide-1 and glucagon receptor dual agonist IBI362 (LY3305677) in Chinese patients with type 2 diabetes". Nature Communications. 13 (1): 3613. doi:10.1038/s41467-022-31328-x. ISSN 2041-1723. PMC 9232612. PMID 35750681.
- ^ Ji, Linong; Gao, Leili; Jiang, Hongwei; Yang, Jing; Yu, Lei; Wen, Jie; Cai, Chenghang; Deng, Huan; Feng, Liqi; Song, Baili; Ma, Qingyang; Qian, Lei (December 2022). "Safety and efficacy of a GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) 9 mg and 10 mg in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple-ascending-dose phase 1b trial". eClinicalMedicine. 54: 101691. doi:10.1016/j.eclinm.2022.101691. PMC 9561728. PMID 36247927.
- ^ Ji, Linong; Jiang, Hongwei; An, Pei; Deng, Huan; Liu, Meng; Li, Li; Feng, Liqi; Song, Baili; Han-Zhang, Han; Ma, Qingyang; Qian, Lei (September 2021). "IBI362 (LY3305677), a weekly-dose GLP-1 and glucagon receptor dual agonist, in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple ascending dose phase 1b study". eClinicalMedicine. 39: 101088. doi:10.1016/j.eclinm.2021.101088. PMC 8374649. PMID 34430840.
- ^ "Next-gen Lilly obesity drug slashes weight in Innovent study—but is it enough to rival Mounjaro?". Retrieved 4 November 2023.